Literature DB >> 18554281

Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations.

E Barrow1, W Alduaij, L Robinson, A Shenton, T Clancy, F Lalloo, J Hill, D G Evans.   

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant condition caused by inactivating mutations of DNA mismatch repair (MMR) genes. An accurate estimation of colorectal cancer risk for mutation carriers is essential for counselling and rationalizing screening programmes. Families were referred on the basis of clinical criteria. Tumour immunohistochemistry and microsatellite testing were performed. Appropriate patients underwent sequencing of all relevant exons of the MMR genes. Proven and obligate mutation carriers and first-degree relatives (FDRs) with an HNPCC spectrum cancer were considered mutation carriers, as were a proportion of untested, unaffected FDRs based on the proportion of unaffected relatives testing positive in each age group. The cumulative lifetime risk was calculated by Kaplan-Meier analysis. Three hundred and forty-one colorectal cancers in 839 proven, obligate, or assumed mutation carriers were analysed. The cumulative risk to age 70 years for all mutation carriers combined was 50.4% (95% CI 47.8-52.9). The cumulative risk in males was 54.3% (95% CI 50.7-57.8), which was significantly higher than in females (log rank p = 0.02) who had a risk of 46.3% (95% CI 42.8-49.9). These penetrance estimates from HNPCC families attending high-risk clinics have been corrected for ascertainment bias and are appropriate risks for those referred to a high-risk clinic. Current colonoscopic screening guidelines are appropriate.

Entities:  

Mesh:

Year:  2008        PMID: 18554281     DOI: 10.1111/j.1399-0004.2008.01035.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  39 in total

1.  Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline.

Authors:  Scott M Weissman; Randall Burt; James Church; Steve Erdman; Heather Hampel; Spring Holter; Kory Jasperson; Matt F Kalady; Joy Larsen Haidle; Henry T Lynch; Selvi Palaniappan; Paul E Wise; Leigha Senter
Journal:  J Genet Couns       Date:  2011-12-14       Impact factor: 2.537

Review 2.  Do lifestyle factors influence colorectal cancer risk in Lynch syndrome?

Authors:  Fränzel J B van Duijnhoven; Akke Botma; Renate Winkels; Fokko M Nagengast; Hans F A Vasen; Ellen Kampman
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 3.  Lynch syndrome: clinical, pathological, and genetic insights.

Authors:  Ralph Schneider; Claudia Schneider; Matthias Kloor; Alois Fürst; Gabriela Möslein
Journal:  Langenbecks Arch Surg       Date:  2012-02-24       Impact factor: 3.445

4.  Current Lynch syndrome tumor screening practices: a survey of genetic counselors.

Authors:  Stephanie A Cohen
Journal:  J Genet Couns       Date:  2013-05-15       Impact factor: 2.537

Review 5.  Early-onset colorectal cancer: a sporadic or inherited disease?

Authors:  Vittoria Stigliano; Lupe Sanchez-Mete; Aline Martayan; Marcello Anti
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 6.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version).

Authors:  Hideyuki Ishida; Tatsuro Yamaguchi; Kohji Tanakaya; Kiwamu Akagi; Yasuhiro Inoue; Kensuke Kumamoto; Hideki Shimodaira; Shigeki Sekine; Toshiaki Tanaka; Akiko Chino; Naohiro Tomita; Takeshi Nakajima; Hirotoshi Hasegawa; Takao Hinoi; Akira Hirasawa; Yasuyuki Miyakura; Yoshie Murakami; Kei Muro; Yoichi Ajioka; Yojiro Hashiguchi; Yoshinori Ito; Yutaka Saito; Tetsuya Hamaguchi; Megumi Ishiguro; Soichiro Ishihara; Yukihide Kanemitsu; Hiroshi Kawano; Yusuke Kinugasa; Norihiro Kokudo; Keiko Murofushi; Takako Nakajima; Shiro Oka; Yoshiharu Sakai; Akihiko Tsuji; Keisuke Uehara; Hideki Ueno; Kentaro Yamazaki; Masahiro Yoshida; Takayuki Yoshino; Narikazu Boku; Takahiro Fujimori; Michio Itabashi; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Yasuhiro Shimada; Keiichi Takahashi; Shinji Tanaka; Osamu Tsuruta; Toshiharu Yamaguchi; Kenichi Sugihara; Toshiaki Watanabe
Journal:  J Anus Rectum Colon       Date:  2018-05-25

7.  Age-Dependent Cancer Risk Is Not Different in between MSH2 and MLH1 Mutation Carriers.

Authors:  Sylviane Olschwang; Kai Yu; Christine Lasset; Stéphanie Baert-Desurmont; Marie-Pierre Buisine; Qing Wang; Pierre Hutter; Etienne Rouleau; Olivier Caron; Violaine Bourdon; Gilles Thomas
Journal:  J Cancer Epidemiol       Date:  2009-03-08

8.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.

Authors:  Naohiro Tomita; Hideyuki Ishida; Kohji Tanakaya; Tatsuro Yamaguchi; Kensuke Kumamoto; Toshiaki Tanaka; Takao Hinoi; Yasuyuki Miyakura; Hirotoshi Hasegawa; Tetsuji Takayama; Hideki Ishikawa; Takeshi Nakajima; Akiko Chino; Hideki Shimodaira; Akira Hirasawa; Yoshiko Nakayama; Shigeki Sekine; Kazuo Tamura; Kiwamu Akagi; Yuko Kawasaki; Hirotoshi Kobayashi; Masami Arai; Michio Itabashi; Yojiro Hashiguchi; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2021-06-29       Impact factor: 3.402

Review 9.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

10.  Penetrance of HNPCC-related cancers in a retrolective cohort of 12 large Newfoundland families carrying a MSH2 founder mutation: an evaluation using modified segregation models.

Authors:  Karen A Kopciuk; Yun-Hee Choi; Elena Parkhomenko; Patrick Parfrey; John McLaughlin; Jane Green; Laurent Briollais
Journal:  Hered Cancer Clin Pract       Date:  2009-10-28       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.